Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 14 | 2022 | 893 | 1.190 |
Why?
|
| Alcohol Drinking | 12 | 2022 | 805 | 1.180 |
Why?
|
| Avoidance Learning | 5 | 2021 | 58 | 1.150 |
Why?
|
| Binge Drinking | 6 | 2016 | 50 | 1.100 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2021 | 79 | 0.930 |
Why?
|
| Potassium Channels | 3 | 2018 | 55 | 0.830 |
Why?
|
| Nicotine | 3 | 2011 | 350 | 0.780 |
Why?
|
| Alcohol-Related Disorders | 2 | 2018 | 95 | 0.680 |
Why?
|
| Ventral Tegmental Area | 2 | 2018 | 74 | 0.660 |
Why?
|
| Taste | 3 | 2008 | 49 | 0.610 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 7 | 0.580 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 15 | 0.580 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 47 | 0.530 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2016 | 24 | 0.530 |
Why?
|
| Models, Animal | 1 | 2017 | 252 | 0.530 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 627 | 0.460 |
Why?
|
| Neural Pathways | 1 | 2016 | 324 | 0.460 |
Why?
|
| Motor Activity | 3 | 2018 | 621 | 0.420 |
Why?
|
| Alcoholism | 4 | 2022 | 1109 | 0.390 |
Why?
|
| Conditioning, Classical | 2 | 2011 | 57 | 0.390 |
Why?
|
| Animals | 23 | 2022 | 20881 | 0.380 |
Why?
|
| Mice | 16 | 2022 | 8474 | 0.340 |
Why?
|
| Septal Nuclei | 3 | 2021 | 31 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 11 | 2021 | 2791 | 0.300 |
Why?
|
| Behavior, Animal | 3 | 2021 | 470 | 0.290 |
Why?
|
| Nicotinic Agonists | 1 | 2007 | 111 | 0.280 |
Why?
|
| Anxiety | 4 | 2022 | 422 | 0.260 |
Why?
|
| Neurons | 3 | 2021 | 881 | 0.250 |
Why?
|
| Receptors, Neuropeptide Y | 2 | 2015 | 5 | 0.230 |
Why?
|
| Neuropeptide Y | 2 | 2015 | 11 | 0.230 |
Why?
|
| Parvalbumins | 1 | 2022 | 29 | 0.210 |
Why?
|
| Male | 17 | 2021 | 37321 | 0.190 |
Why?
|
| Thalamus | 1 | 2021 | 82 | 0.190 |
Why?
|
| Limbic System | 1 | 2021 | 106 | 0.190 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2020 | 27 | 0.180 |
Why?
|
| Mice, Inbred DBA | 2 | 2016 | 120 | 0.170 |
Why?
|
| Computational Biology | 1 | 2020 | 190 | 0.170 |
Why?
|
| Mood Disorders | 1 | 2020 | 132 | 0.160 |
Why?
|
| Synapses | 1 | 2021 | 222 | 0.160 |
Why?
|
| Rats | 5 | 2011 | 5300 | 0.160 |
Why?
|
| KCNQ Potassium Channels | 1 | 2018 | 8 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 1745 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2015 | 2689 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 274 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 498 | 0.150 |
Why?
|
| Neuroimmunomodulation | 1 | 2017 | 16 | 0.140 |
Why?
|
| Rats, Long-Evans | 2 | 2008 | 203 | 0.140 |
Why?
|
| Phenylenediamines | 1 | 2016 | 16 | 0.140 |
Why?
|
| Action Potentials | 1 | 2018 | 223 | 0.140 |
Why?
|
| Membrane Transport Modulators | 1 | 2016 | 23 | 0.140 |
Why?
|
| Acenaphthenes | 1 | 2016 | 1 | 0.140 |
Why?
|
| Urocortins | 1 | 2016 | 1 | 0.140 |
Why?
|
| Designer Drugs | 1 | 2016 | 7 | 0.140 |
Why?
|
| Carbamates | 1 | 2016 | 41 | 0.130 |
Why?
|
| Clozapine | 1 | 2016 | 46 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2017 | 111 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Receptors, Melanocortin | 1 | 2015 | 5 | 0.130 |
Why?
|
| Pyrroles | 1 | 2016 | 83 | 0.130 |
Why?
|
| Animal Feed | 1 | 2015 | 52 | 0.130 |
Why?
|
| Phenotype | 2 | 2021 | 947 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 88 | 0.130 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 640 | 0.120 |
Why?
|
| Hypothalamus | 1 | 2015 | 78 | 0.120 |
Why?
|
| Basolateral Nuclear Complex | 1 | 2015 | 28 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2016 | 178 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2015 | 85 | 0.120 |
Why?
|
| Neural Inhibition | 1 | 2015 | 80 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2020 | 824 | 0.120 |
Why?
|
| Histones | 1 | 2014 | 111 | 0.110 |
Why?
|
| Hypothermia | 2 | 2011 | 37 | 0.110 |
Why?
|
| Amygdala | 2 | 2012 | 159 | 0.110 |
Why?
|
| Darkness | 1 | 2013 | 27 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1033 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1293 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2021 | 295 | 0.100 |
Why?
|
| Conditioning, Operant | 3 | 2012 | 241 | 0.100 |
Why?
|
| Extinction, Psychological | 2 | 2011 | 240 | 0.100 |
Why?
|
| Mutation | 1 | 2017 | 1213 | 0.100 |
Why?
|
| Diet | 1 | 2015 | 514 | 0.100 |
Why?
|
| Taste Perception | 1 | 2011 | 7 | 0.100 |
Why?
|
| Biogenic Monoamines | 1 | 2011 | 18 | 0.100 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2011 | 19 | 0.090 |
Why?
|
| Female | 7 | 2021 | 38074 | 0.090 |
Why?
|
| Excitatory Postsynaptic Potentials | 2 | 2021 | 87 | 0.090 |
Why?
|
| Nucleus Accumbens | 1 | 2014 | 417 | 0.090 |
Why?
|
| Central Nervous System Depressants | 2 | 2012 | 182 | 0.090 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2011 | 92 | 0.090 |
Why?
|
| Affect | 2 | 2022 | 218 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2011 | 2083 | 0.080 |
Why?
|
| Body Temperature Regulation | 1 | 2008 | 29 | 0.080 |
Why?
|
| Saccharin | 1 | 2007 | 4 | 0.080 |
Why?
|
| Association Learning | 1 | 2008 | 36 | 0.080 |
Why?
|
| Sweetening Agents | 1 | 2007 | 23 | 0.070 |
Why?
|
| Inhibitory Postsynaptic Potentials | 2 | 2021 | 25 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 215 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2008 | 289 | 0.070 |
Why?
|
| Reward | 2 | 2022 | 201 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1864 | 0.070 |
Why?
|
| Self Administration | 1 | 2007 | 419 | 0.070 |
Why?
|
| Motivation | 1 | 2008 | 561 | 0.060 |
Why?
|
| Sucrose | 1 | 2022 | 58 | 0.050 |
Why?
|
| Alcohol Abstinence | 1 | 2022 | 23 | 0.050 |
Why?
|
| Integrases | 1 | 2021 | 31 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2020 | 187 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 442 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 426 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 929 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2021 | 332 | 0.040 |
Why?
|
| Alcohol Deterrents | 1 | 2018 | 86 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2550 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2018 | 371 | 0.040 |
Why?
|
| Dopamine | 1 | 2018 | 474 | 0.030 |
Why?
|
| Encephalitis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Drug-Seeking Behavior | 1 | 2018 | 213 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 77 | 0.030 |
Why?
|
| Eating | 1 | 2015 | 119 | 0.030 |
Why?
|
| Locomotion | 1 | 2015 | 135 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 786 | 0.030 |
Why?
|
| Acetylation | 1 | 2014 | 94 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 218 | 0.030 |
Why?
|
| Humans | 2 | 2018 | 68618 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2012 | 50 | 0.030 |
Why?
|
| Arginine | 1 | 2012 | 102 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 1664 | 0.020 |
Why?
|
| Putamen | 1 | 2011 | 35 | 0.020 |
Why?
|
| Caudate Nucleus | 1 | 2011 | 56 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 765 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2011 | 156 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 483 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2008 | 29 | 0.020 |
Why?
|
| Dynorphins | 1 | 2008 | 69 | 0.020 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2008 | 37 | 0.020 |
Why?
|
| Naltrexone | 1 | 2008 | 195 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 329 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 4655 | 0.020 |
Why?
|